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Background: Hypertension is highly prevalent among adults, and is the most important modifiable risk factor for
cardiovascular events, in particular stroke. Decreasing sodium intake has the potential to prevent or delay the
development of hypertension and improve blood pressure control, independently of blood pressure lowering
drugs, among hypertensive patients. Despite guidelines recommending a low sodium diet, especially for hypertensive
individuals, sodium intake remains higher than recommended. A recent systematic review indicated that the efficacious
counselling methods described in published trials are not suitable for hypertension management by primary care
providers in Canada in the present form. The primary reason for the lack of feasibility is that interventions for
sodium restriction in these trials was not limited to counselling, but included provision of food, prepared meals,
or intensive inpatient training sessions.
Methods/design: This is a parallel, randomized, controlled, open-label trial with blinded endpoints. Inclusion criteria are
adult patients with hypertension with high dietary sodium intake (defined as ≥100 mmol/day). The control arm
will receive usual care, and the intervention arm will receive usual care and an additional structured counselling
session by a registered dietitian, with four follow-up telephone support sessions over four weeks. The two primary
outcomes are change in sodium intake from baseline, as measured by a change in 24-hour urinary sodium
measurements at four weeks and one year. Secondary outcomes include change in blood pressure (as measured by
24-hour ambulatory monitoring), change in 24-hour urinary potassium, and change in body weight at the same time
points.
Discussion: Though decreasing sodium intake has been reported to be efficacious in lowering blood pressure, there
exists a gap in the evidence for an effective intervention that could be easily translated into clinical practice. If successful,
our intervention would be suitable for outpatient programs such as hypertension clinics or interprofessional family
practices (family health teams). A negative, or partially negative (positive effect at four weeks with attrition by 12 months)
trial outcome also has significant implications for healthcare delivery and use of resources.
Trial registration: The trial was registered with Clinicaltrials.gov (identifier: NCT02283697) on 2 November 2014.
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Hypertension is highly prevalent among adult Canadians
(about 20 % in those aged 20 to 79 years), and is the most
important modifiable risk factor for cardiovascular events,
in particular stroke [1, 2]. The relationship between sodium
intake as assessed from 24-hour urinary sodium and age-
related increase in systolic blood pressure (BP) has been
well established [3]. Furthermore, decreasing sodium intake
has the potential to prevent or delay the development of
hypertension and improve BP control, independently of BP
lowering drugs, among hypertensive patients [4, 5]. With
this in mind, it is not surprising that the restriction of diet-
ary salt intake for the prevention and management of
hypertension is a strongly endorsed health measure [6–8].
However, Health Canada survey findings indicate that the
current average salt intake among Canadian adult males
and females ranges between 6.5 and 9 g (or between 2,600
and 3,600 mg of sodium)/day, with men consuming more
dietary salt than women [9]. However, according to the
2014 Canadian Hypertension Education Program (CHEP)
guidelines, sodium intake should not exceed 2,000 mg/day
[6]. Indeed, an individual would have to reduce their so-
dium intake by 50 to 70 %, depending on their hypertensive
status, to reach the CHEP recommended target [6].
This magnitude of salt intake reduction to levels envis-
aged by the CHEP is projected to have a significant impact
on BP level and on adverse vascular outcomes of hyper-
tension [10]. It is estimated that 1.65 million deaths world-
wide were due to cardiovascular causes from a daily
sodium consumption of more than 2 g [11]. It is also esti-
mated that the associated healthcare cost savings would
amount to 10 to 24 billion US dollars annually [10]. Given
the proven relationship between the dietary sodium intake
and hypertension, the known risk of adverse outcomes of
hypertension, and the individual and public health finan-
cial, health, and social benefits of low salt intake, it is
somewhat surprising that salt intake remains stagnantly
high over the last several decades, despite many public
health efforts [9, 12].
Canadian adults are mostly diagnosed with high BP
during routine annual check-ups with their family phys-
ician. Family physicians are expected to establish the
diagnosis and to initiate hypertension therapy. Since the
majority of hypertensive patients in Canada have mild
and uncomplicated hypertension, primary care physi-
cians also continue to manage a significant proportion
of patients with hypertension [13]. Thus, with regards to
the treatment of hypertension, family physicians are
really the ‘front-liners’, who introduce both lifestyle mod-
ifications and pharmacological interventions to individ-
ual patients and make further adjustments in therapy to
achieve target BP. The CHEP provides detailed guide-
lines on the diagnosis and treatment of hypertension to
Canadian family physicians [6]. These guidelines includespecific algorithms for the diagnosis and management of
hypertension [6]. In the setting of very busy primary care
practices, these algorithms are crucial to facilitate mak-
ing the diagnosis, initiating and maintaining hyperten-
sion therapy, and ensuring that patients are engaged and
informed.
However, in contrast to the specific algorithms provided
for the diagnosis and pharmacological treatment of hyper-
tension, algorithms on how to achieve the rigorous targets
for dietary sodium intake are absent [6]. CHEP specifically
endorses the Dietary Approaches to Stop Hypertension
(DASH) diet [4] because it is well described, reproducible,
and leads to sustainable decreases in salt intake. However,
what is not clear from the guidelines is details about the
most efficacious method of counselling on dietary sodium
restriction to achieve potentially very rigorous targets, how
to assess compliance and progress of an individual patient
with regards to sodium intake restriction, and finally how
to include these potentially time-consuming tasks into the
daily routine of busy Canadian family physicians. Indeed,
lack of time and inadequate compensations have been
reported as the strongest barriers to providing nutrition
guidance by US and Canadian primary practices [14–16].
These results should not come as surprise once one appre-
ciates how much time primary care physicians in North
America have ‘available’ for their patients. For example, re-
sults of the National Review of Medicine 2006 Practice
Management Survey showed that majority of family physi-
cians in Canada see 26 to 50 patients per day [17]. Further,
42 % of 700 responders reported an increase in patient load
in the last 12 months [17]. A recent systematic review indi-
cated that there are well-described, and therefore, easy to
reproduce counselling methods on efficacious low sodium
diets [18]. However, none of these counselling methods are
suitable for hypertension management by primary care pro-
viders in Canada in the present form. The primary reason
for the lack of feasibility in the outpatient settings in
Canada is that interventions for salt restriction in these tri-
als was not limited to mere counselling, but included
provision of food, prepared meals, or intensive inpatient
training sessions [18].
Hence, given that data from clinical trials support the
efficacy of dietary sodium reduction in lowering BP, but
with a paucity of research into clinically feasible and lo-
gistically simple methods of implementing this, we have
designed a pragmatic clinical trial to test if the addition
of lead counselling by a registered dietitian, in compari-




The study is designed as a pragmatic, parallel, open-label,
randomized controlled trial with blinded endpoints. Since
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be possible. However, the primary outcome of the study is
a change in urinary sodium, which is an objective end-
point, and the laboratory personnel performing the meas-
urement and the research personnel analyzing the
measurements will be blinded to treatment assignment.
The randomization process will consist of a computer-
generated random listing of the treatment allocations in
variable permuted blocks, with concealment of allocation
using sealed envelopes. The Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
checklist and the World Health Organization (WHO)
Trial Registration Data Set Checklist are also presented
(see Additional file 1 and Table 1).
Setting
The trial will be conducted at a tertiary care academic
health sciences centre in Canada. The setting is a Renal
Hypertension Clinic, which receives consultations for
difficult-to-control hypertension. Potential participants
will be identified from the clinic and approached by a
member of the health care team to ascertain their will-
ingness to be contacted by the research personnel. Once
the patient has agreed to be contacted by the research
personnel, a member of the research team will contact
the patient and will briefly describe the trial and deter-
mine if the patient is interested in participating. If so, a
copy of the consent form will be provided to the patient.
After reading the consent form, if the patient expresses
interest, they will be asked to attend a screening visit
where a study team member will explain the protocol,
and potential risks and benefits again in detail. If the pa-
tient chooses to enroll in the study, the study coordin-
ator will obtain written informed consent and ensure all
necessary information is obtained. The research coordin-
ator will ensure that, during the consent process, there
is no overture of coercion, duress, or undue incentive.
Study population
The inclusion criteria for this study are as follows:
1. Adult patients (>18 years);
2. Patients with hypertension defined as either daytime
BP readings above 140/90 mmHg (as assessed from
24-hour ambulatory BP monitoring (ABPM)) without
treatment, or any patient with treated hypertension
irrespective of BP load; and
3. Dietary sodium intake >100 mmol/day, as measured
with 24-hour urinary collection.
The exclusion criteria for this study are as follows:
1. Pregnant patients (since pregnancy and hypertension
requires different dietary advice);2. Patients with an estimated glomerular filtration
rate (eGFR, measured using the MDRD formula
[19]) <45 ml/min/1.75 m2;
3. Patients with an active infection (defined as being on
active anti-microbial treatment);
4. Patients with recent acute coronary syndrome
(myocardial infarction or revascularisation) within
the last six months;
5. Patients with psychiatric disorders and/or who are
otherwise unable to sign consent; and
6. Patients with clinically manifested generalized and/
or cardiac volume overload (including ascites and
congestive heart failure), who may require
immediate changes in diuretic therapy (at the
discretion of treating hypertension specialist).
Interventions
Patients randomized to the control arm will receive a
standard endorsement of low salt diet and other non-
pharmacological interventions, such as moderation of al-
cohol intake, optimal body weight, and daily exercise,
from a hypertension nurse and physician, which is the
standard of care.
Patients randomized to the intervention arm will re-
ceive usual care and an additional one-on-one (family
members allowed) one-hour long counselling session
from a registered dietitian. The dietitian will assess the
patient’s eating habits and identify factors involved in
high sodium intake, focusing on portion size, processed
food, snacking habits, eating out, and reading labels.
Apart from counselling tailored to the cause and source
of high sodium, a handbook with advice on decreasing
sodium in diet will be provided. This will be followed by
four weekly, 30-minute long follow-up sessions by tele-
phone to provide support, address compliance, and an-
swer any questions raised by patients and family
members.
Measurements
We will evaluate dietary sodium intake by measurement
of 24-hour urinary sodium before and after counselling.
We will not allow changes in diuretic therapy within a
week prior to counselling and throughout the four weeks
of the trial duration, and patients in whom an urgent
change in diuretic therapy is anticipated will be excluded
from the trial. This approach will ensure that baseline
24-hour urinary sodium reflects steady state and repre-
sents 24-hour dietary sodium intake. Similarly, changes
in 24-hour urinary sodium four weeks post-intervention
will reflect changes in patients’ dietary sodium intake
with no interference of the effect of diuretics. In studies
using the DASH diet and longer follow-up periods, the
effect of intervention is attenuated once the food is not
provided to the patient, and so does the effect on BP
Table 1 World Health Organization Trial Registration Data Set Checklist
Data category Information
Primary registry and trial
identifying number
ClinicalTrials.gov: NCT02283697
Date of registration in primary
registry
4 November 2014
Secondary identifying numbers -
Source(s) of monetary or material
support
The Ottawa Hospital Academic Medical Organisation
Primary sponsor The Ottawa Hospital Academic Medical Organisation
Secondary sponsor(s) Ottawa Hospital Research Institute
Contact for public queries Gigi van den Hoef +16137985555 ext 82514
Contact for scientific queries Marcel Ruzicka, MD PhD
Swapnil Hiremath, MD MPH
Public title Sodium counselling in hypertension
Scientific title Does Pragmatically Structured Outpatient Dietary Counselling Reduce Sodium Intake in Hypertensive Patients?
Countries of recruitment Canada
Health condition(s) or problem(s)
studied
Hypertension
Intervention(s) Active comparator: standard of care + Dietitian lead counselling
Control comparator: standard of care
Key inclusion and exclusion
criteria
Inclusion criteria:
- adult patients (>18 years) with
- hypertension defined as daytime blood pressure (BP) readings above 140/90 mmHg (as assessed from 24-hour
ambulatory BP monitoring (ABPM)) without treatment
- and/or any patient with treated hypertension irrespective of BP load based on 24-hour ABPM.
Exclusion criteria:
- Pregnant patients (since pregnancy and hypertension requires different dietary advice)
Patients with following conditions:
- eGFR <45 ml/min/1.75 m2,
- active infection (defined as being on active anti-microbial treatment),
- recent acute coronary syndrome (myocardial infarction or revascularisation) within 6 months,
- psychiatric disorders and/or otherwise unable to sign consent,
- patients with clinically manifested generalized and/or cardiac volume overload (including ascites and congestive
heart failure) who may require immediate changes in diuretic therapy (at the discretion of treating hypertension
specialist).
- Inability to provide informed consent
Study type Interventional
Allocation: randomized
Intervention model: parallel assignment
Masking: blinding of outcomes assessor only
Primary purpose: treatment
Date of first enrolment June 2015 (anticipated)
Target sample size 120
Recruitment status Funded, approved, enrolment to begin soon
Primary outcome(s) Change in 24-hour urinary sodium from baseline at 4 weeks and 12 months
Key secondary outcomes Changes in 24-hour urinary potassium, body weight, and BP
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assessed 12 months post-intervention to assess for the
long term effectiveness of this method.
24-hour ABPM will be done before and after dietary
counselling within 24 to 48 hours of 24-hour urinary
collection for sodium. This will allow us to correlate any
changes in dietary sodium intake with changes in overall
BP load. In addition, we will also measure changes in
24-hour urinary potassium, and changes in body weight.
Lastly, a simple one-page survey will be administered to
all patients to assess their perceptions of potential bar-
riers to dietary sodium reduction at the end of the
12-month follow-up period. The time points of the
intervention and data collection are shown in a sche-
matic form in Fig. 1.
Analysis
Though blinding of the patients is not possible for a be-
havioral intervention such as this, the assessment of the
outcome, which is an objective measurement, will be done
in a blinded fashion. All the study personnel collating and
analyzing this data will be blinded to the treatment assign-
ment. In addition, the laboratory personnel who will be
measuring the urinary sodium (which is the primary out-
come) will be blinded to treatment assignment.
We will have two primary efficacy outcomes, reduction
in 24-hour urine sodium at four weeks and reduction in
24-hour urine sodium at 12 months. While we anticipate
little or no loss to follow-up at four weeks, it is possible
that there might be as much as a 30 % loss at 12 months.
The minimal clinically important difference according to
the CHEP guidelines is a 40 mmol reduction. Our reviewFig. 1 Study flow diagram showing time points at which data will be colle
RN: Registered Nurse; ABPM: Ambulatory Blood Pressure Monitoringof the literature identified a range of possible standard
deviations from 31 to 51 mmol. To be conservative, we
assumed 51 mmol for the sample size estimation.
Adjusting for multiple testing, this means that we would
need 42 patients per group to have 90 % power in a
t-test. In order to ensure this many patients at
12 months, we will recruit 60 patients per group. This
calculation is conservative since it is based on a paired
t-test but we will analyze the outcomes with the more
powerful analysis of covariance (ANCOVA model.
Secondary outcomes will include changes in daytime
average systolic BP by 24-hour ABPM, changes in dietary
potassium intake assessed from 24-hour urinary potassium,
and changes in body weight, all at the same time points as
described for the primary outcome measure (four weeks as
well as 12 months post-intervention). We will also do a
one-page survey of participants at the end of the study
(12 months) to identify potential barriers to salt restriction
in diet.
All analysis will be conducted using the intention-to-
treat principle. Any missing data will be imputed using
multiple imputations. No interim analyses are planned,
and there are no stopping rules for this trial. Subgroup
analyses are planned based on tertiles of baseline so-
dium intake and source of high sodium intake (as iden-
tified by dietitian). We will also assess the association
between changes in sodium, potassium intake, and
changes in body weight and BP. In addition, we will
conduct a sensitivity analysis based on achieved sodium
intake and its relationship with BP. All the subgroup
and sensitivity analyses will be hypothesis-generating
and will be interpreted accordingly.cted. Figure legend: HT: Hypertension; MD: Medical Doctor, physician;
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A trial management group involving the Principal Investi-
gators (MR and SH), two Co-Investigators (TR, AK), and
the Study Coordinator (JW) will review, implement, and
supervise all aspects of this trial. Since this is a low risk
intervention, consisting of counselling alone, we do not
have a data safety and monitoring committee. Participants
will be explicitly informed as part of the consent process
that they can decide to withdraw from the study at any
time if they so desire, without affecting their medical care.
Ethical issues and trial registration
The trial will be conducted in accordance with Health
Canada’s Good Clinical Practice guidelines and in ac-
cordance with the current Declaration of Helsinki and
the Tri-Council Policy Statement: Ethical Conduct for
Research Involving Humans [22, 23]. The study protocol
and informed consent forms have been approved by the
Ottawa Health Science Network Research Ethics Board
(Protocol ID: 20140717-01H). The trial was registered at
the US National Institutes of Health (Clinicaltrials.gov
identifier: NCT02283697) on 2 November 2014.
Discussion
High salt intake is directly responsible for elevated BP in
a significant proportion of hypertensive patients. Reduc-
tion of salt consumption decreases BP in hypertensive
patients. Low salt diets, such as the DASH-sodium, are
fairly well established. However, counselling methods
leading to reduced salt intake suitable for outpatients
using available healthcare resources and patients’ time
are not [18, 21]. In addition, even counselling methods
that did result in reduced salt intake by methods such as
hospitalization of patients and food provision, or many
hours of counselling from dietitians for outpatients com-
bined with food provision and/or access to communal
kitchens, have been reported to lose their efficacy by six
months after the active counselling ceased [20]. Hence
there a need for an effective counselling method on low
sodium intake pragmatically using available healthcare
resources that can lead to a successful and sustained
lower sodium intake.
Our approach took inspiration from a proven strategy of
a one-time intensive counselling session followed by weekly
telephone reminders which significantly improves adher-
ence to BP lowering drug treatments [24, 25]. This new but
proven method is adapted for counselling on low salt intake
as we believe that if it is successful, it would be suitable for
outpatient programs such as hypertension clinics or inter-
professional family practices (family health teams). This
study will also assess the long term efficacy of our counsel-
ling strategy, as well as more important outcome with
regards to BP control population-wide. A negative, or par-
tially negative (positive effect at four weeks with attrition by12 months) trial outcome also has significant implications
for healthcare delivery and use of resources. A completely
negative trial should lead to a search for new methods to
change patients’ most intimate behaviors such as dietary
habits. A partially negative trial may just indicate that fur-
ther interventions are necessary to help with persistence for
some or all patients.
Trial status
Trial recruitment is anticipated to begin in June 2015.
The responsibility for study design, data collection, inter-
pretation, and writing of the report and decision to sub-
mit the report for publication resides with the research
team, and not the funding body or sponsor. The re-
search team will have access and control over the trial
dataset. The findings of the trial will be disseminated
using presentation at national conferences (Canadian
Hypertension Conference, Canadian Society of Nephrology)
and by publication in peer-reviewed journals. We will
follow the Consolidated Standards of Reporting Trials
(CONSORT) checklist, along with the extensions for
pragmatic trials [26] and non-pharmacologic interven-
tions [27], in preparing the final report. The Inter-
national Committee of Medical Journal Editors criteria
will be used to determine authorship of the final trial
results, with no usage of any professional writers. Trial
participant-level data and statistical codes will be made
available on request.
Additional file
Additional file 1: SPIRIT 2013 Checklist. Contains the recommended
items to address in a clinical trial protocol and related documents based
on Standard Protocol Items: recommendations for Interventional Trials
(SPIRIT).
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